Regulatory Approvals - SINTX received FDA 510(k) clearance for the SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a significant milestone for commercial entry into reconstructive foot and ankle surgery in the U.S.[6] Financial Performance - Total revenue for Q3 2025 was $208 million, a decrease of 74.0% compared to $799 million in Q3 2024[17]. - Product revenue for the nine months ended September 30, 2025, was $541 million, down 48.7% from $1,054 million in the same period of 2024[17]. - Gross profit for Q3 2025 was $93 million, significantly lower than $589 million in Q3 2024, reflecting a gross margin decline[17]. - The net loss for Q3 2025 was $3,539 million, compared to a net loss of $6,239 million in Q3 2024, indicating an improvement[17]. - The company reported a net loss attributable to common stockholders of $10,258 million for Q3 2025, compared to $6,239 million in Q3 2024[17]. - Basic net loss per share for Q3 2025 was $(1.19), compared to $(6.96) in Q3 2024[17]. - Adjusted EBITDA loss was $2.3 million in Q3 2025, a significant improvement from a loss of $6.1 million in Q3 2024[6]. - Adjusted EBITDA for Q3 2025 was $(2,308) million, an improvement from $(6,085) million in Q3 2024[19]. Operating Expenses - Operating expenses decreased by 51% year-over-year to approximately $3.4 million, leading to an operating loss of $3.4 million compared to $6.4 million in Q3 2024[6]. - Total operating expenses for Q3 2025 were $3,448 million, a decrease of 50.7% from $6,997 million in Q3 2024[17]. - Research and development expenses for Q3 2025 were $1,264 million, up 58.7% from $796 million in Q3 2024[17]. Liquidity and Cash Management - Cash and cash equivalents increased to $6.25 million as of September 30, 2025, up from $3.60 million on December 31, 2024, reflecting improved liquidity management[6]. - SINTX raised an additional $4.3 million in gross proceeds through warrant inducement and common stock warrant exercises, strengthening its liquidity position[6]. Asset and Liability Management - Total assets increased to $11.36 million as of September 30, 2025, compared to $9.41 million on December 31, 2024[15]. - Total liabilities rose to $7.30 million as of September 30, 2025, up from $5.52 million on December 31, 2024[15]. Strategic Initiatives - The company plans to prepare the SINAPTIC wedge system for launch and expand clinical engagement in targeted surgical specialties[7]. - The company executed a sublease of the Armor facility, estimated to save approximately $950,000 in lease costs over the sublease term[6]. Shareholder Information - Weighted average common shares outstanding for Q3 2025 were 2,963,539, significantly higher than 896,305 in Q3 2024[17].

Financial Performance - Q3 2025 revenue increased by 20% year-over-year to $162.5 million, up from $135.3 million in Q3 2024[3] - Q3 2025 net income rose 139% year-over-year to $5.5 million, compared to $2.3 million in Q3 2024, resulting in earnings of $0.08 per share[5] - Q3 2025 gross profit increased by 40% year-over-year to $28.2 million, with a gross profit margin of 17.4%, up from 14.9% in Q3 2024[4] - Adjusted EBITDA for Q3 2025 was $16.1 million, a 75% increase from $9.2 million in Q3 2024[6] - Revenue for the nine months ended September 30, 2025, reached $498,816,000, compared to $436,876,000 in 2024, marking an increase of about 14.2%[31] - Adjusted EBITDA for the nine months ended September 30, 2025, was $54,866,000, up from $26,731,000 in 2024, reflecting a growth of approximately 105.5%[29] - Net income for the nine months ended September 30, 2025, was $29,985,000, a significant increase from $2,421,000 in the same period of 2024, representing a growth of approximately 1,142%[23] Cash and Liquidity - Cash, cash equivalents, and cryptocurrencies totaled $72.9 million as of September 30, 2025, up from $31.0 million at the end of 2024[6] - Cash and cash equivalents at the end of the period were $59,266,000, compared to $32,229,000 at the end of September 2024, indicating a growth of approximately 83.8%[23] - The company reported a net cash flow from operating activities of $33,033,000 for the nine months ended September 30, 2025, compared to $17,253,000 in 2024, indicating a strong operational cash generation[23] - Net cash flows from operations for the first nine months of 2025 were $33.0 million, compared to $17.3 million in the same period of 2024[7] Operational Metrics - The increase in revenue was driven by increased kiosk deployment and higher median transaction sizes[3] - The company has over 9,000 kiosk locations, maintaining the largest market share in North America as of August 2025[11] - Total operating expenses for Q3 2025 were $18.3 million, compared to $16.9 million in Q3 2024, primarily due to higher non-cash stock compensation[4] Profitability and Margins - Adjusted Gross Profit for the nine months ended September 30, 2025, was $95,986,000, compared to $66,028,000 in 2024, representing an increase of about 45.0%[31] - The Adjusted EBITDA margin for the nine months ended September 30, 2025, was 11.0%, compared to 6.1% in 2024, indicating improved operational efficiency[29] - The gross profit margin for the nine months ended September 30, 2025, was 18.1%, up from 13.3% in 2024, reflecting better cost management[31] Future Outlook - The company expects Q4 2025 revenue to be approximately $112 to $115 million, reflecting typical seasonality and regulatory impacts[8] Balance Sheet - Total liabilities as of September 30, 2025, amounted to $104,262,000, an increase from $96,590,000 at the end of 2024[21] - Total stockholders' equity as of September 30, 2025, was $21,016,000, compared to a deficit of $16,486,000 at the end of 2024, showing a positive turnaround[21]

Exhibit 99.1 Synergy CHC Corp. Reports Third Quarter 2025 Financial Results and its Eleventh Consecutive Quarter of Profitability Third Quarter 2025 Financial Results Revenue in the third quarter of 2025 was $8.0 million, up 12.4% compared to $7.1 million in the third quarter of 2024. WESTBROOK, Maine, November 13, 2025 – Synergy CHC Corp. (NASDAQ: SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, is announcing its financial results for the three months ended September 30, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-40903 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) | Delaware | 84-3559776 | | ...

EXHIBIT 99.1 Oblong Reports Q3 2025 Results Oblong, Inc. Grows TAO Treasury to 21,822 Tokens in Q3 2025: All Holdings Fully Staked on Bittensor Network November 13, 2025 — DENVER, CO — Oblong, Inc. (Nasdaq: OBLG), a digital asset treasury company, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Treasury Growth and Staking Operations Oblong invested $6.3 million to acquire 16,517 TAO tokens during Q3 at an average price of $384 per toke ...

Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Patent Covering IV Dosing Regimen for GTx-104 Princeton, NJ, November 13, 2025 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financ ...

Exhibit 99.1 Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Pat ...

Financial Performance - Net sales for Q3 2025 were $30,482, a decrease of 2.9% from $31,407 in Q3 2024[8] - Gross profit increased to $5,025 in Q3 2025, compared to $3,835 in Q3 2024, reflecting a gross margin improvement[8] - Operating expenses totaled $4,080 in Q3 2025, down from $4,302 in Q3 2024, indicating a reduction of 5.2%[8] - The company reported a net loss of $146 in Q3 2025, an improvement from a net loss of $739 in Q3 2024[8] - The company reported a comprehensive loss of $167 in Q3 2025, compared to a comprehensive loss of $516 in Q3 2024[8] - The company reported a net loss of $739 for the three months ended September 30, 2024, and a net loss of $146 for the three months ended September 30, 2025[16] - Total net sales for the three months ended September 30, 2025, were $30,482 million, a slight decrease from $31,407 million in the same period of 2024, representing a 2.9% decline[33] - For the nine months ended September 30, 2025, total net sales were $88,052, down $11,461 or 11.5% from $99,513 in the prior year[71] Assets and Liabilities - Total current assets increased to $59,206 as of September 30, 2025, up from $55,315 at the end of 2024[10] - Total liabilities rose to $41,400 as of September 30, 2025, compared to $38,430 at the end of 2024, reflecting an increase of 5.1%[10] - As of September 30, 2025, total shareholders' equity was $33,357, a decrease from $35,690 as of June 30, 2024, reflecting a net loss of $1,149 during the period[16] - Long-lived tangible assets as of September 30, 2025, totaled $12,628, down from $14,371 as of December 31, 2024[59] Cash Flow and Financing - Cash at the end of Q3 2025 was $1,271, an increase from $916 at the beginning of the period[12] - Net cash used in operating activities for the nine months ended September 30, 2025, was $2,865, a slight improvement from $3,043 in the same period of 2024[12] - Cash provided by financing activities was $3,218 million for the nine months ended September 30, 2025, compared to $3,561 million in the prior-year period, driven by line of credit advances[92] - Cash provided by inventory was $2,823 million for the nine months ended September 30, 2025, compared to cash used of $(922) million in the prior-year period, reflecting a reduction in inventory balances[95] - The company entered into a $15,000 million Senior Secured Revolving Line of Credit on February 29, 2024, with a current outstanding amount of $12,030 million as of September 30, 2025[36][39] - As of September 30, 2025, the company had unused availability on the line of credit of $2,970 million, subject to a month-end cap based on minimum liquidity requirements[40] - The company plans to refinance its $12,030 million outstanding Revolver, which matures on August 31, 2026, to alleviate substantial doubt about its ability to continue as a going concern[93] Operational Metrics - Medical Device sales for the nine months ended September 30, 2025, were $23,971 million, compared to $26,493 million in 2024, reflecting a decrease of 9.5%[33] - The 90-day shipment backlog as of September 30, 2025, was $31,322, an increase of 17.8% from $26,592 at the beginning of the quarter[73] - Total order backlog as of September 30, 2025, was $77,292, representing a 1.4% decrease from $78,351 at the beginning of the quarter but a 10.8% increase year-over-year[74] - The company operates primarily in the Medical Device market, which accounts for over 50% of its net sales[58] Expenses and Costs - The company incurred interest expenses of $273 in Q3 2025, compared to $216 in Q3 2024, representing a 26.4% increase[8] - Total lease costs for the three months ended September 30, 2025, were $686 million, down from $840 million in the same period of 2024, a decrease of 17.5%[44] - Stock-based compensation expense for the three months ended September 30, 2025 was $134 million, compared to $127 million in 2024[47] - Total compensation expense related to stock options was $84 million for the three months ended September 30, 2025, down from $61 million in 2024[49] - General and administrative expenses decreased to 8.5% of net sales for the three months ended September 30, 2025, down from 9.4% in 2024, primarily due to lower incentive compensation accruals[84] Taxation - The effective tax rate for the three months ended September 30, 2025 was 122%, compared to 8% for the same period in 2024[56] - The company plans to optimize tax cash payments and overall tax expense following the restoration of the ability to immediately deduct domestic research and development expenses[57] Restructuring and Facility Changes - Restructuring charges incurred during the nine months ended September 30, 2025, totaled $266, related to the closure of the Blue Earth facility and staff reductions[60] - The company completed the sale of the Blue Earth manufacturing facility for $500, which approximated book value, with no gain or loss recorded[27] - The company has facilities in Minnesota, Mexico, and China, with the Blue Earth facility closure completed in December 2024[66] Future Outlook and Compliance - The company expects to transfer substantially all remaining performance obligations for contract assets to receivables within 90 days as of September 30, 2025[35] - The Company must maintain a leverage ratio of 2.5 times and a minimum fixed charge coverage ratio of 1.25 times starting from Q4 2025[97] - Adjusted EBITDA requirements are set at least $1,000 for Q2 2025, $1,300 for Q3 2025, and $1,600 for Q4 2025 and thereafter[97] - The Company must maintain liquidity of at least $2,500 as per the Second Amendment to the Revolver[97]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | Delaware | 001-39070 | 32-0463781 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (I.R.S. Employer | | of incorporation) | File Number) | Identification No.) | 1000 Skokie B ...

Financial Position - As of September 30, 2025, the company's cash, cash equivalents, and investments totaled $143.7 million, expected to last through at least December 31, 2027[144]. - The company reported a net cash inflow of $81.86 million for the nine months ended September 30, 2025, compared to a net cash outflow of $1.25 million for the same period in 2024, marking an increase of $83.11 million[187]. - Cumulative negative cash flows from operations resulted in an accumulated deficit of approximately $84.3 million as of September 30, 2025[184]. - Cash used in investing activities increased by $1,264,561 during the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to net investments in U.S. Treasury securities[189]. - Cash flow provided by financing activities increased by $88,803,654 during the nine months ended September 30, 2025, mainly due to net proceeds of approximately $91.9 million from the September 2025 capital raise and share repurchase[190]. Share Transactions - The company sold 1,181,540 shares at $16.25 per share on October 30, 2024, yielding net proceeds of approximately $17.8 million[146]. - A public offering on December 23, 2024, resulted in the sale of 798,655 shares at $23.79 per share, generating net proceeds of approximately $37.4 million[147]. - On September 23, 2025, the company sold 1,034,433 shares at $67.67 per share, with net proceeds of approximately $91.9 million after a $35 million share repurchase[148]. Research and Development - ALXN1840 for Wilson disease has shown three-times greater copper mobilization compared to standard-of-care in a Phase 3 trial, with a Least Square Mean Difference of 2.18 µmol/L (p< 0.0001)[152]. - The company plans to submit a New Drug Application (NDA) for ALXN1840 to the FDA in early 2026[159]. - MNPR-101-Zr has received regulatory clearance in Australia for a Phase 1 imaging trial, with positive early clinical data reported[160]. - The FDA cleared the IND application for MNPR-101-Lu on September 26, 2025, for a Phase 1 trial targeting uPAR-expressing tumors[163]. - The company is actively exploring opportunities to expand its radiopharmaceutical pipeline through internal development efforts[164]. - The company has two active human clinical trials for its MNPR-101 radiopharmaceutical program, focusing on advanced cancers[170]. - Research and development (R&D) expenses for Q3 2025 were $2.59 million, a 163% increase from $0.98 million in Q3 2024, primarily due to increased manufacturing activities related to ALXN1840[177]. - R&D expenses for the nine months ended September 30, 2025, were $5.96 million, a 93% increase from $3.08 million in the same period in 2024[178]. General and Administrative Expenses - General and administrative (G&A) expenses for Q3 2025 were $1.50 million, up 154% from $0.59 million in Q3 2024, mainly due to increased Board compensation and personnel expenses[179]. - G&A expenses for the nine months ended September 30, 2025, were $4.59 million, up 129% from $2.01 million in the same period in 2024[180]. Financial Performance - The net loss for Q3 2025 was $3.44 million, compared to a net loss of $1.30 million in Q3 2024, reflecting a variance of $2.13 million[176]. - Interest income for Q3 2025 increased by $556,129 compared to Q3 2024, attributed to higher bank balances and interest earned on U.S. Treasury securities[181]. - The company has not generated any revenue from product sales to date and does not expect to do so until regulatory approval and commercialization of drug candidates are achieved[191]. - Anticipated expenses are expected to increase significantly as the company continues research, development, and clinical trials for current and future drug candidates[192]. Obligations and Agreements - The company has obligations to pay Alexion milestone payments of up to $94.0 million for regulatory approval and sales-related milestones, along with tiered royalties based on net sales ranging from 10% to 20%[200]. - A long-term, non-exclusive master supply agreement with NorthStar for the therapeutic radioisotope actinium-225 was established, clarifying economic terms and jointly-developed intellectual property rights[202]. - The company has a non-exclusive license with XOMA Ltd. for humanization technology, with potential milestone payments totaling up to $14.925 million, but no payments have been made as of October 31, 2025[203]. Future Financing - The company expects to finance future cash needs primarily through equity offerings, debt financings, strategic collaborations, and grant funding, which may dilute current stockholders' ownership[197]. Lease and Legal Proceedings - The company entered into a 36-month lease for executive headquarters at a monthly rate of $3,580, along with additional leases for laboratory space[205]. - The company has not been involved in any adverse material legal proceedings to date[206]. Management Experience - The management team has extensive experience, having achieved four drug approvals and three diagnostic device approvals in the U.S. and EU[165].